A Phase 1 Single Dose Study Evaluating the Relative Oral Bioavailability of a New Formulation of ABT-263 in Subjects With Cancer.

Trial Profile

A Phase 1 Single Dose Study Evaluating the Relative Oral Bioavailability of a New Formulation of ABT-263 in Subjects With Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Navitoclax (Primary)
  • Indications Brain metastases; Chronic lymphocytic leukaemia; Lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 28 Jan 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
    • 28 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Actual initiation date changed from Sep 2009 to Oct 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top